BIM
EGRX

Bogle Investment Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Bogle Investment Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7,819
Closed -$364K – 121
2020
Q4 		$364K Sell
7,819
-5,881
-43% -$275K 0.58% 90
2020
Q3 		$582K Buy
+13,700
New +$599K 0.17% 129
2015
Q3 		– Sell
-159,049
Closed -$12.9M – 452
2015
Q2 		$12.9M Buy
159,049
+29,080
+22% +$1.89M 0.96% 12
2015
Q1 		$5.44M Buy
+129,969
New +$3.69M 0.38% 93

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SGCIA
Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bogle Investment Management's EGRX Position: Q1 2021 in Review

Bogle Investment Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2021, closing a stake of 7,819 shares — an estimated $364K sold.

Bogle Investment Management first reported a position in EGRX in Q1 2015 and held it in 4 quarters. The position peaked at $12.9M in Q2 2015. 155 funds tracked by Wall St. Rank hold EGRX as of Q1 2021.

  • Bogle Investment Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
  • Bogle Investment Management sold 7,819 Eagle Pharmaceuticals, Inc. shares in Q1 2021, an estimated $364K.
  • Bogle Investment Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 4 quarters.
  • Bogle Investment Management's Eagle Pharmaceuticals, Inc. position peaked at $12.9M in Q2 2015.
  • 155 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2021.

Based on Bogle Investment Management's 13F filing for Q1 2021.